Details for Patent: 7,311,924

Title:	Compositions and methods for treating cancer
Abstract:	This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.
Inventor(s):	Sarris; Andreas H (Houston, TX), Cabanillas; Fernando (Houston, TX), Logan; Patricia M (Vancouver, CA), Burge; Clive T R (Brentwood Bay, CA), Goldie; James H (Vancouver, CA), Webb; Murray S (Delta, CA), Madden; Thomas D (Vancouver, CA), Semple; Sean C (Vancouver, CA), Ahkong; Quet F (Surrey, CA), Klimuk; Sandra K (Vancouver, CA)
Assignee:	Hana Biosciences, Inc. (South San Francisco, CA)
Filing Date:	Apr 03, 2003
Application Number:	10/407,864
Claims:	1. A method of treating a solid tumor in a mammal, comprising administering to said mammal a pharmaceutical composition comprising liposome-encapsulated vinorelbine, wherein the said solid tumor is selected from the group consisting of lung cancer, breast cancer, colon cancer, prostate cancer and renal cancer. 2. The method of claim 1, wherein the pharmaceutical composition is administered to said mammal every seven days. 3. The method of claim 2, wherein said pharmaceutical composition is administered to said mammal for at least three weeks. 4. The method of claim 2, wherein the therapeutic index of the pharmaceutical composition is greater than the therapeutic index of free vinorelbine. 5. The method of claim 4, wherein the therapeutic index of the pharmaceutical composition is at least 1.4-fold greater than the therapeutic index of free vinorelbine. 6. The method of claim 4, wherein the therapeutic index of the pharmaceutical composition is at least 2-fold greater than the therapeutic index of free vinorelbine. 7. The method of claim 4, wherein the therapeutic index of the pharmaceutical composition is at least 2.4-fold greater than the therapeutic index of free vinorelbine. 8. The method of claim 4, wherein the therapeutic index of the pharmaceutical composition is at least 3.6-fold greater than the therapeutic index of free vinorelbine. 9. The method of claim 1, wherein the liposome comprises sphingomyelin and cholesterol. 10. The method of claim 9, wherein the ratio of sphingomyelin to cholesterol is between 75/25 and 50/50 (mol % sphingomyelin/mol % cholesterol). 11. The method of claim 10, wherein the ration of sphingomyelin to cholesterol is approximately 55:45 (mol % sphingomyelin/mol % cholesterol). 12. The method of claim 1, wherein the ratio of vinorelbine to lipid is 0.001-0.5:1 (w/w). 13. The method of claim 12, wherein the ratio of vinorelbine to lipid is at least 0.1:1 (w/w). 14. The method of claim 13, wherein the ratio of vinorelbine to lipid is 0.1-0.3:1 (w/w).